PRAME-CAR-iNKT

N/A

Report date: 2026/03/16 20:01:47
First In Class

Base Information

Drug NamePRAME-CAR-iNKT
Drug Alias NameAllogeneic iNKT cell therapyCF-033
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-Melanoma antigen preferentially expressed in tumors
TargetsMelanoma antigen preferentially expressed in tumors
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMiNK Therapeutics IncC-Further
China Registration ClassN/A

Develop Information

Active CompaniesC-FurtherMiNK Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A